JP2021518335A5 - - Google Patents

Info

Publication number
JP2021518335A5
JP2021518335A5 JP2020548916A JP2020548916A JP2021518335A5 JP 2021518335 A5 JP2021518335 A5 JP 2021518335A5 JP 2020548916 A JP2020548916 A JP 2020548916A JP 2020548916 A JP2020548916 A JP 2020548916A JP 2021518335 A5 JP2021518335 A5 JP 2021518335A5
Authority
JP
Japan
Prior art keywords
cancer
compound
product according
pharmaceutical
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548916A
Other languages
English (en)
Japanese (ja)
Other versions
JP7266942B2 (ja
JP2021518335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052009 external-priority patent/WO2019175776A1/en
Publication of JP2021518335A publication Critical patent/JP2021518335A/ja
Publication of JP2021518335A5 publication Critical patent/JP2021518335A5/ja
Application granted granted Critical
Publication of JP7266942B2 publication Critical patent/JP7266942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548916A 2018-03-15 2019-03-12 Sting(インターフェロン遺伝子刺激因子)のシクロペンタン-ベースのモジュレーター Active JP7266942B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US62/643,467 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US62/666,204 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US62/742,532 2018-10-08
US201962809990P 2019-02-25 2019-02-25
US62/809,990 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (3)

Publication Number Publication Date
JP2021518335A JP2021518335A (ja) 2021-08-02
JP2021518335A5 true JP2021518335A5 (cg-RX-API-DMAC7.html) 2022-03-16
JP7266942B2 JP7266942B2 (ja) 2023-05-01

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020548916A Active JP7266942B2 (ja) 2018-03-15 2019-03-12 Sting(インターフェロン遺伝子刺激因子)のシクロペンタン-ベースのモジュレーター

Country Status (25)

Country Link
US (4) US10538542B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765474B1 (cg-RX-API-DMAC7.html)
JP (1) JP7266942B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200131878A (cg-RX-API-DMAC7.html)
CN (1) CN111918871A (cg-RX-API-DMAC7.html)
AU (1) AU2019234043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093631C (cg-RX-API-DMAC7.html)
CL (1) CL2020002352A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200382A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000160A (cg-RX-API-DMAC7.html)
EC (1) ECSP20057847A (cg-RX-API-DMAC7.html)
ES (1) ES2923298T3 (cg-RX-API-DMAC7.html)
IL (1) IL277278A (cg-RX-API-DMAC7.html)
MA (1) MA52012A (cg-RX-API-DMAC7.html)
MX (1) MX2020009587A (cg-RX-API-DMAC7.html)
NI (1) NI202000058A (cg-RX-API-DMAC7.html)
PE (1) PE20210412A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551486A1 (cg-RX-API-DMAC7.html)
PY (1) PY1919127A (cg-RX-API-DMAC7.html)
RU (1) RU2020130048A (cg-RX-API-DMAC7.html)
SG (1) SG11202008102VA (cg-RX-API-DMAC7.html)
TW (1) TWI741268B (cg-RX-API-DMAC7.html)
UY (1) UY38145A (cg-RX-API-DMAC7.html)
WO (1) WO2019175776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
PH12022550709A1 (en) * 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4259642A1 (en) * 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Similar Documents

Publication Publication Date Title
JP2021512131A5 (cg-RX-API-DMAC7.html)
JP2025024006A5 (cg-RX-API-DMAC7.html)
JP2007530526A5 (cg-RX-API-DMAC7.html)
HRP20201334T1 (hr) Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
JP2020105190A5 (cg-RX-API-DMAC7.html)
RU2014102935A (ru) Кризотиниб для применения в лечении рака
Zhou et al. Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives
JP2018510850A5 (cg-RX-API-DMAC7.html)
JP2020143134A5 (cg-RX-API-DMAC7.html)
RU2005128791A (ru) Лекарственные формы, содержащие ag013736
EA201992418A1 (ru) Бициклические соединения и их применение в лечении рака
JP2015232006A5 (cg-RX-API-DMAC7.html)
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
RU2013134359A (ru) Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
WO2018016563A1 (en) Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
JP2019524748A5 (cg-RX-API-DMAC7.html)
JP2020530844A5 (cg-RX-API-DMAC7.html)
JP2017536397A5 (cg-RX-API-DMAC7.html)
JP2023521167A5 (cg-RX-API-DMAC7.html)
JP2022530272A5 (cg-RX-API-DMAC7.html)
Xu et al. Glycoprotein nonmetastatic melanoma protein B accelerates tumorigenesis of cervical cancer in vitro by regulating the Wnt/β-catenin pathway
Kulesza-Bronczyk et al. Quality of life during the first year after breast cancer resection
Yuan et al. Dual action of pyrimidine derivatives: Targeting tamoxifen resistance in breast cancer
RU2020108510A (ru) Антипресенилиновое антитело для использования в профилактике и/или лечении рака
Hwang et al. Cancer-related pelvic pain